Request a quote

GMP saRNA Production & LNP Manufacturing

Our GMP saRNA-LNP manufacturing platform produces high-quality, potent saRNA and LNPs, accelerating the development of RNA therapies and vaccines.

Request a Consultation

Comprehensive GMP saRNA-LNP Manufacturing Platform

uBriGene’s talented technical and regulatory teams have extensive experience in the GMP manufacturing and releasing self-amplifying RNA (saRNA) to support RNA therapies and vaccines. Our advanced LNP encapsulation technology ensures high encapsulation rate and well-controlled LNP size.

GMP saRNA-LNP Production Advantages

Comprehensive GMP saRNA-LNP Services

GMP plasmid template preparation
saRNA LNP process development & manufacturing, and QC testing
LNP formulation services

Robust Plug-and Play Platform Manufacturing Processes

High yield & high purity saRNA, achieving up to 80% integrity
Achieve >90% encapsulation efficiency with novel microfluidic LNP encapsulation technology.
Polycistronic design available

Comprehensive Analytics

RNA circularization efficiency testing
Potency testing
LNP encapsulation efficiency, particle size, density, and polydispersity index (PDI) characterization.

Regulatory Support

Expert advanced therapeutics IND-filing support 
Provide custom regional regulatory support 
DMF framework in-place

Need GMP LNP saRNA Production?

With our GMP saRNA production platform and optimized LNP RNA delivery technologies, we fast-track self-amplifying RNA (saRNA) manufacturing for scalable RNA-based therapies and RNA vaccines.

Integrated services, from plasmids to RNA lipid nanoparticles (LNP)

Polycistronic options

Ask the saRNA Expert
ubriGene's saRNA-LNP production service workflow.

Analytical and QC Testing for GMP saRNA and LNP

saRNA QC Testing:

Test Item Method
Identity mRNA sequence identity RT-PCR+Sanger Sequencing
Content Concentration UV absorbance
Purity 5’ capping efficiency CE/LC-MS
3’ polyA tail length CE/LC-MS
A260/A280 UV absorbance
RNA integrity HPLC
mRNA fragments
Aggregate quantitation
Residual protein Qubit / MicroBCA
dsRNA ELISA
Residual DNA template qPCR
Residual solvents Residual ethanol(GC-MS)
Potency Expression of target protein Cell-based assay
Safety Sterility Culture method
Endotoxin GEL-CLOT Method
Physical/chemical Properties Appearance Visual method
pH pH

*Outsourced testing

LNP QC Testing:

Test Item Method
Identity Identity of lipids RP-HPLC
Integrity LNP size and polydispersity Dynamic light scattering (DLS)
Content Concentration Fluorescence-based assay
Purity Aggregate quantitation SEC-HPLC
Encapsulation efficiency Fluorescence-based assay,
Residual solvents Residual ethanol
Potency Expression of target protein Cell-based assay
Safety Sterility Culture method
Endotoxin GEL-CLOT Method
Physical/Chemical Properties Appearance Visual method
pH pH
Osmolality Osmolality
Subvisible particles Light blockage methods
Extractable volume Volumetric method

*Outsourced testing

Request a Quote

Polycistronic saRNA Design

Diagram of polycistronic saRNA amplified transcription producing more than one protein from a single saRNA.

High Quality saRNA, Analyzed by CE

RFU graph depicting the high-quality saRNA produced as analyzed by capillary electrophoresis.

High Protein Expression from Polycistronic saRNA

Fluorescent microscopy images showing high protein expression from polycistronic saRNA.

Note: The same amount of saRNA and mRNA were used in this experiment. Due to its larger size, the molar concentration of saRNA is significantly lower compared to linear mRNA.

The polycistronic saRNA contains NeonGreen and RFP expression cassettes. The same amount of saRNA and mRNA (1ug, respectively) were transfected into HEK293 cells using PEI. Fluorescence images were captured 72 hours post transfection.

Much Longer Protein Expression from saRNA Compared to mRNA

Line graph of RFU over 16 days showing saRNA has much longer protein expression than mRNA.

Lipid nanoparticles containing NeonGreen-teLuc saRNA, circRNA, and linear mRNA (1 pmol / 1E5 cells) were added to HEK293 cells, and Bioluminescence quantification was performed up to 16 days post-treatment.

Request a Consultation

Frequently asked questions

saRNA, or self-amplifying RNA, contains a gene of interest and the elements required for intracellular self-amplification, enabling prolonged protein expression from a relatively small amount of RNA. This can potentially support lower RNA doses compared with conventional mRNA approaches, depending on the application and formulation. uBriGene's saRNA platform supports therapeutic and vaccine development, including polycistronic saRNA designs for expressing multiple genes from a single molecule.

uBriGene can supply saRNA in single tubes suspended in nuclease-free water at 1 mg/mL. For saRNA-LNP products, RNA can be supplied in single tubes suspended in Tris buffer or PBS at 0.1 mg/mL RNA concentration. saRNA can be provided as bulk RNA or formulated into LNPs according to the requirements of the development program.

Typically, saRNA ranges from 8K to 13K nucleotides in length, but longer sequences can be produced if necessary.

uBriGene provides end-to-end saRNA manufacturing services, supporting both research-grade and GMP saRNA production. Its platform also supports GMP saRNA-LNP process development, manufacturing, and QC testing, using microfluidic LNP encapsulation technology that achieves >90% encapsulation efficiency. The platform supports integrated manufacturing from GMP plasmid template preparation through saRNA production and LNP formulation.

Because saRNA is substantially longer than conventional mRNA, maintaining RNA integrity during manufacturing and purification is a key challenge. uBriGene's GMP saRNA platform reports up to 80% saRNA integrity, with analytical testing including RNA integrity, fragments, aggregates, residual DNA, residual protein, dsRNA, and other quality attributes. Actual performance depends on the saRNA sequence and manufacturing process.

Yes, uBriGene can carry out LNP formulation studies, testing various lipids, components, and cell culture conditions to identify the most efficient delivery method for your target cells.

uBriGene supports GMP saRNA-LNP programs with regulatory and CMC support, including GMP manufacturing, QC testing, analytical characterization, and regulatory documentation. Its U.S. and Asia facilities support global cell and gene therapy programs, with an established DMF framework and an active FDA DMF #31266 for the Germantown, Maryland facility. Products tested at the site have also supported FDA IND clearances.

uBriGene's GMP saRNA manufacturing workflow can include GMP plasmid template preparation, saRNA production, purification, analytical and QC testing, LNP formulation, and product release. The integrated platform supports process development, manufacturing, and LNP formulation to help transition saRNA programs toward clinical development.

uBriGene's GMP saRNA QC testing includes sequence identity, concentration, 5′ capping efficiency, poly(A) tail length, RNA integrity, aggregates, residual protein, dsRNA, residual DNA template, residual solvents, potency, sterility, and endotoxin. saRNA-LNP testing includes lipid identity, particle size, PDI, concentration, encapsulation efficiency, potency, sterility, endotoxin, pH, osmolality, subvisible particles, and extractable volume

uBriGene's microfluidic LNP encapsulation technology achieves >90% encapsulation efficiency for saRNA-LNP production. LNP quality is further characterized by particle size, polydispersity index (PDI), concentration, aggregate content, potency, and other release and quality attributes.

Yes. uBriGene's polycistronic saRNA design enables multiple genes of interest to be expressed from a single self-amplifying RNA molecule. The platform is designed for programs requiring expression of more than one protein and can support therapeutic applications involving multiple gene products.

Need GMP LNP saRNA Production?

With our GMP saRNA production platform and optimized LNP RNA delivery technologies, we fast-track self-amplifying RNA (saRNA) manufacturing for scalable RNA-based therapies and RNA vaccines.

Integrated services, from plasmids to RNA lipid nanoparticles (LNP)

Polycistronic options

Ask the saRNA Expert